Literature DB >> 24247284

Cardiorenal syndrome--current understanding and future perspectives.

Branko Braam1, Jaap A Joles2, Amir H Danishwar1, Carlo A Gaillard3.   

Abstract

Combined cardiac and renal dysfunction has gained considerable attention. Hypotheses about its pathogenesis have been formulated, albeit based on a relatively small body of experimental studies, and a clinical classification system has been proposed. Cardiorenal syndrome, as presently defined, comprises a heterogeneous group of acute and chronic clinical conditions, in which the failure of one organ (heart or kidney) initiates or aggravates failure of the other. This conceptual framework, however, has two major drawbacks: the first is that, despite worldwide interest, universally accepted definitions of cardiorenal syndrome are lacking and characterization of heart and kidney failure is not uniform. This lack of consistency hampers experimental studies on mechanisms of the disease. The second is that, although progress has been made in developing hypotheses for the pathogenesis of cardiorenal syndrome, these initiatives are at an impasse. No hierarchy has been identified in the myriad of haemodynamic and non-haemodynamic factors mediating cardiorenal syndrome. This Review discusses current understanding of cardiorenal syndrome and provides a roadmap for further studies in this field. Ultimately, discussion of the definition and characterization issues and of the lack of organization among pathogenetic factors is hoped to contribute to further advancement of this complex field.

Entities:  

Mesh:

Year:  2013        PMID: 24247284     DOI: 10.1038/nrneph.2013.250

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  100 in total

1.  Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease.

Authors:  Luis F Ramos; Jane Kane; Ellen McMonagle; Phuong Le; Pingsheng Wu; Ayumi Shintani; Talat Alp Ikizler; Jonathan Himmelfarb
Journal:  J Ren Nutr       Date:  2010-12-24       Impact factor: 3.655

2.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

3.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Authors:  G Ligtenberg; P J Blankestijn; P L Oey; I H Klein; L T Dijkhorst-Oei; F Boomsma; G H Wieneke; A C van Huffelen; H A Koomans
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 4.  Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.

Authors:  Kim E Jie; Marianne C Verhaar; Maarten-Jan M Cramer; Karien van der Putten; Carlo A J M Gaillard; Pieter A Doevendans; Hein A Koomans; Jaap A Joles; Branko Braam
Journal:  Am J Physiol Renal Physiol       Date:  2006-08-01

5.  A functional model of the rat kidney.

Authors:  R Kainer
Journal:  J Math Biol       Date:  1979-01-23       Impact factor: 2.259

6.  A mathematical model of fluid transport in the kidney.

Authors:  P K Jensen; O Christensen; K Steven
Journal:  Acta Physiol Scand       Date:  1981-08

Review 7.  Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling.

Authors:  Weiguo Chen; Michael O Daines; Gurjit K Khurana Hershey
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

8.  Treatment of anemia with darbepoetin alfa in systolic heart failure.

Authors:  Karl Swedberg; James B Young; Inder S Anand; Sunfa Cheng; Akshay S Desai; Rafael Diaz; Aldo P Maggioni; John J V McMurray; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Yan Sun; Michal Tendera; Dirk J van Veldhuisen
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

Review 9.  Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.

Authors:  Karien van der Putten; Branko Braam; Kim E Jie; Carlo A J M Gaillard
Journal:  Nat Clin Pract Nephrol       Date:  2008-01

Review 10.  Redox regulation of the afferent arteriole and tubuloglomerular feedback.

Authors:  C S Wilcox
Journal:  Acta Physiol Scand       Date:  2003-11
View more
  56 in total

1.  Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.

Authors:  L Červenka; V Melenovský; Z Husková; A Sporková; M Bürgelová; P Škaroupková; S H Hwang; B D Hammock; J D Imig; J Sadowski
Journal:  Physiol Res       Date:  2015-06-05       Impact factor: 1.881

2.  Determination of renal function and injury using near-infrared fluorimetry in experimental cardiorenal syndrome.

Authors:  Mizuko Ikeda; Rumie Wakasaki; Katie J Schenning; Thomas Swide; Jeong Heon Lee; M Bernie Miller; Hak Soo Choi; Sharon Anderson; Michael P Hutchens
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-11

3.  IL-6 Contributes to Corneal Nerve Degeneration after Herpes Simplex Virus Type I Infection.

Authors:  Ana J Chucair-Elliott; Jeremy Jinkins; Meghan M Carr; Daniel J J Carr
Journal:  Am J Pathol       Date:  2016-08-03       Impact factor: 4.307

4.  Risk prediction in infective endocarditis by modified MELD-XI score.

Authors:  Peng-Cheng He; Xue-Biao Wei; Si-Ni Luo; Xiao-Lan Chen; Zu-Hui Ke; Dan-Qing Yu; Ji-Yan Chen; Yuan-Hui Liu; Ning Tan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-29       Impact factor: 3.267

Review 5.  Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.

Authors:  Valeria Rudomanova; Burns C Blaxall
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-25       Impact factor: 5.187

Review 6.  Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.

Authors:  Yoshitsugu Obi; Taehee Kim; Csaba P Kovesdy; Alpesh N Amin; Kamyar Kalantar-Zadeh
Journal:  Cardiorenal Med       Date:  2015-11-06       Impact factor: 2.041

7.  Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

Authors:  P Kala; L Sedláková; P Škaroupková; L Kopkan; Z Vaňourková; M Táborský; A Nishiyama; S H Hwang; B D Hammock; J Sadowski; V Melenovský; J D Imig; L Červenka
Journal:  Physiol Res       Date:  2018-03-12       Impact factor: 1.881

Review 8.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 9.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

10.  Delayed kidney injury following coronary angiography.

Authors:  Feng Wang; Cheng Peng; Guangyuan Zhang; Qing Zhao; Changyou Xuan; Meng Wei; Niansong Wang
Journal:  Exp Ther Med       Date:  2016-05-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.